Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL) (LenVoDex)
Phase I/II Trial of Lenalidomide in Combination With Vorinostat and Dexamethasone as Therapy in Relapsed or Refractory Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)
Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Terminated
slow recruitment
Listed as NCT00972842, this PHASE1/PHASE2 trial focuses on Peripheral T-Cell Non-Hodgkin's Lymphoma and remains terminated or withdrawn. Sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie, it has been updated 7 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE1/PHASE2
-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2021 — Jun 2022 [monthly]
Terminated PHASE1_PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
First recorded
Sep 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Celgene Corporation
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .